Owner CuraGen Corporation Amgen Fremont Inc.

Inventors Rastelli, Luca; Jeffers, Michael E.; Xiao, Feng; Karkaria, Cyrus; Tse, Kam Fai; Foord, Orit; Lichensten, Henri; Davagnino, Juan; Larochelle, William J.; Herrmann, John; Mezes, Peter; Liang, Meina; Pollack, Vincent A.; Klakamp, Scott; Chapoval, Andrei; Jia, Xiao-Chi; Torgov, Michael; Ara, Gulshan

Agent Cullens

Pub. Number AU-B-2005322410

PCT Pub. Number WO2006/071441

Priority 60/733,779 07.11.05 US; 60/632,023 30.11.04 US

Filing date 30 November 2005

Wipo publication date 6 July 2006

Acceptance publication date 10 November 2011

C07K 16/30 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A61P 35/00 (2006.01) Antineoplastic agents

C07K 19/00 (2006.01) Hybrid peptides

C12N 1/21 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/13 (2006.01) Mutation or genetic engineering - Immunoglobulins

C12N 15/63 (2006.01) Mutation or genetic engineering - Introduction of foreign genetic material using vectors

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

G01N 33/577 (2006.01) Investigating or analysing materials by specific methods not covered by groups - involving monoclonal antibodies